AbbVie Inc (ABBV)vsVeracyte Inc (VCYT)
ABBV
AbbVie Inc
$286.40
-0.14%
HEALTHCARE · Cap: $504.37B
VCYT
Veracyte Inc
$50.31
+0.06%
HEALTHCARE · Cap: $4.04B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 11359% more annual revenue ($64.39B vs $561.90M). VCYT leads profitability with a 20.4% profit margin vs 9.8%. VCYT trades at a lower P/E of 35.9x. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
VCYT
Buy60
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-86.7%
Fair Value
$152.97
Current Price
$286.40
$133.43 premium
Margin of Safety
+58.3%
Fair Value
$86.20
Current Price
$50.31
$35.89 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 40.0%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Earnings expanding 288.9% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Keeps 20 of every $100 in revenue as profit
Reasonable price relative to book value
15.5% revenue growth
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
Premium valuation, high expectations priced in
ROE of 6.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.54 suggests the stock is reasonably priced for its growth.
Bull Case : VCYT
The strongest argument for VCYT centers on EPS Growth, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 20.4% and operating margin at 15.3%. Revenue growth of 15.5% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 80.6x leaves little room for execution misses.
Bear Case : VCYT
The primary concerns for VCYT are P/E Ratio, Return on Equity.
Key Dynamics to Monitor
ABBV profiles as a value stock while VCYT is a growth play — different risk/reward profiles.
VCYT carries more volatility with a beta of 1.95 — expect wider price swings.
VCYT is growing revenue faster at 15.5% — sustainability is the question.
ABBV generates stronger free cash flow (3.1B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (73/100 vs 60/100) and 10.2% revenue growth. VCYT offers better value entry with a 58.3% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Veracyte Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Veracyte, Inc. is a genomic diagnostics company in the United States and internationally. The company is headquartered in South San Francisco, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?